LAURA STOPPEL

Laura Stoppel is a distinguished Principal at RA Capital, a prominent multi-stage investment firm renowned for its deep expertise and significant contributions to the healthcare and life sciences sectors. In her pivotal role, Ms. Stoppel is instrumental in driving RA Capital's mission to identify, evaluate, and invest in companies that are at the forefront of medical innovation. Her work spans the entire investment lifecycle, from rigorous due diligence on potential opportunities to actively supporting portfolio companies as they advance critical research and development.

RA Capital's investment strategy is broad yet focused, encompassing novel therapeutics, platform technologies, medical devices, diagnostics, and research tools designed to address significant unmet medical needs. Laura Stoppel's contributions align perfectly with this strategy, as she leverages her extensive scientific background and investment acumen to pinpoint companies with the potential to revolutionize patient care. She is deeply involved in assessing scientific merit, market potential, and strategic fit for investments across various stages, from nascent startups to established public entities.

Prior to her current role as Principal, Laura Stoppel honed her expertise as an Associate at RA Capital, gaining invaluable experience in the intricacies of life sciences investing. Her career trajectory also includes a significant tenure as an Associate at Flagship Pioneering, a leading venture creation firm, where she was involved in the ideation and launch of numerous groundbreaking biotech companies. This experience provided her with a unique perspective on company building from the ground up. Earlier in her career, Ms. Stoppel served as a Consultant at L.E.K. Consulting, advising pharmaceutical and biotech clients on strategic growth initiatives and market assessments.

Ms. Stoppel's strong foundation in science is underscored by her academic achievements. She earned a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (MIT), where her research contributed to cutting-edge advancements in the field. She also holds a B.S. in Chemical Engineering from Cornell University. This robust scientific and technical background is a critical asset, enabling her to thoroughly evaluate complex scientific data and technological platforms, making her an invaluable member of the RA Capital investment team. While specific individual investments are often a collaborative effort at RA Capital, Ms. Stoppel's expertise contributes to the firm's impressive portfolio of companies driving the next generation of healthcare solutions.